Tuesday, April 1, 2025

BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor

Related stories

Pudu Robotics Launches FlashBot Arm: AI Service Robot

Pudu Robotics, a global leader in service robotics, has...

Workato One Unites AI & Orchestration for Enterprises

Customers now have a single place to rapidly build,...

Hexagon unveils Robotics division for next-gen autonomy

Hexagon announces dedicated Robotics division to accelerate next-generation autonomy,...

TeraRecon & 3DR Labs Expand AI Imaging Partnership

Cloud-based, innovative, AI-powered technologies enable the streamlined delivery of...

Nanoprecise raises $38M in Series C round

Nanoprecise secures $38 million in Series C funding in...
spot_imgspot_img

BeiGene, Ltd., a global biotechnology company, and Ensem Therapeutics, Inc. (ENSEM), a biotechnology company focusing on high-value and difficult-to-drug oncology targets, announced an agreement for BeiGene to acquire an exclusive global license to an Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor.

“We are committed to developing novel molecules with the potential to transform the therapeutic landscape for cancer patients, and this partnership fits well with our strategic focus on breast cancer as an area with tremendous unmet need for innovative treatment options,” said Lai Wang, Ph.D., Global Head of R&D at BeiGene. “This CDK2 inhibitor from ENSEM complements our internally discovered Phase 1 CDK4 inhibitor, which has the potential to improve upon current CDK4/6 inhibitors in some breast cancer patients, and strengthens our early development pipeline in breast cancer and other solid tumors. We are excited to work with ENSEM to bring this molecule into the clinic in the near future.”

Also Read: Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics

Under the terms of the agreement, ENSEM will receive an upfront payment, and will be eligible for additional payments upon the achievement of certain development, regulatory, and commercial milestones, totaling up to $1.33 billion, in addition to tiered royalties.

“We are pleased to partner with BeiGene on the development of this differentiated CDK2 inhibitor,” said Shengfang Jin, Ph.D., President and Chief Executive Officer at ENSEM. “We believe BeiGene is the right partner to advance our first IND-ready asset due to their wealth of expertise in bringing innovative cancer therapies to patients globally. This partnership validates the capabilities of ENSEM’s drug discovery and development team and the ability to rapidly advance potential best-in-class or first-in-class molecules utilizing our Kinetic Ensemble® platform. We look forward to progressing our additional pipeline programs to help patients in need and supporting BeiGene’s important work to take this therapy into clinical trials.”

SOURCE: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img